Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Steps in Outbreak Investigation01:18

Steps in Outbreak Investigation

In the ever-evolving field of public health, statistical analysis serves as a cornerstone for understanding and managing disease outbreaks. By leveraging various statistical tools, health professionals can predict potential outbreaks, analyze ongoing situations, and devise effective responses to mitigate impact. For that to happen, there are a few possible stages of the analysis:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age at Onset Predicts Motor and Non-motor Severity in Cervical Dystonia.

Movement disorders clinical practice·2026
Same author

Social cognition deficits are associated with lower quality of life in cervical dystonia: A single centre study.

Clinical parkinsonism & related disorders·2025
Same author

Visual dysfunction of superior colliculus and lateral geniculate nucleus in idiopathic blepharospasm.

Journal of the neurological sciences·2024
Same author

Corrigendum to: A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10 G>T at the intron 9/exon 10 of the MAPT gene.

Neurobiology of aging·2024
Same author

Social Cognition, Executive Functioning, Mood, and Disability in Cervical Dystonia.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology·2024
Same author

Efficient Bayesian inference of instantaneous reproduction numbers at fine spatial scales, with an application to mapping and nowcasting the Covid-19 epidemic in British local authorities.

Journal of the Royal Statistical Society. Series A, (Statistics in Society)·2024

Related Experiment Video

Updated: Jun 23, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Predicting and preventing the future: actively managing multiple sclerosis.

Michael Hutchinson1

  • 1Department of Neurology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. mhutchin@iol.ie

Practical Neurology
|May 19, 2009
PubMed
Summary

Early treatment optimization for relapsing-remitting multiple sclerosis (MS) is crucial. Tailoring therapies based on initial response can prevent long-term disability and progression to secondary progressive MS.

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: Jun 23, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

  • Neurology
  • Immunology
  • Neuroscience

Background:

  • Relapsing-remitting multiple sclerosis (MS) presents a variable clinical course.
  • Early inflammatory activity in MS significantly contributes to later neurodegenerative changes.
  • A substantial proportion of patients exhibit suboptimal responses to conventional first-line therapies.

Purpose of the Study:

  • To highlight the importance of early disease activity assessment in relapsing-remitting MS.
  • To emphasize the role of advanced therapies in managing MS inflammation.
  • To advocate for treatment optimization strategies to prevent secondary progressive MS.

Main Methods:

  • Review of clinical, demographic, and MRI features for disease activity assessment.
  • Analysis of treatment responses to first-line and second-line therapies.
  • Development of recommendations for treatment optimization based on clinical response.

Main Results:

  • Demographic, clinical, and MRI data aid in predicting MS disease activity and outcomes.
  • First-line therapies partially control relapses, with one-third of patients showing suboptimal response.
  • Highly active second-line therapies demonstrate significant inflammation suppression.

Conclusions:

  • Effective management of early relapsing-remitting MS requires active intervention.
  • Treatment optimization based on initial response is key to preventing disability progression.
  • Early and aggressive management can mitigate the transition to secondary progressive MS.